[OA-09] Assessment of different cut-offs of equivocal HER2 IHC in breast cancer for HER2 ISH to reach appropriate sensitivity, AUC and reduction of ISH assay

The equivocal range of HER2 immunohistochemistry (IHC) is complete weak to moderate staining > 10% of breast cancer cells. This range has increased the numbers of HER2 in situ hybridisation (ISH) testing compared to the previous recommendations. ...